Hello Waveriders,
Today we are adding a new company to are growing list of companies.
Of course we still are featuring the NSAV and SDIG and today we are adding the ARTH.
I feel this is a great combination of price and different avenues of revenue streams.
The NSAV is internet and retail products and food. SDIG is in the internet streaming music and now we have a medical stock.
NSAV just started news this week and I see much more ahead for the company. our new president, Leonardo Genovese & Steven Baritz have been very active in meeting. They are adding a new distribution company that has existing products and revenues.
I look for this new Acquisition to close very quickly and much more for updates from both Steven and Leonardo.
Please add more as we are workign with Asher to allow us some breathing room on the price.
SDIG had a great slow start and seen record volume with an increase of 50% in the first week.
The company is starting up a new streaming music stations on the internet and will be giving away products for listening.
I see they are well funded and have not been diluting.
The company has a low public float recorded as 6 million shares.
By the move this week, I believe the market to be real tight n=on the shares and see a price breakout into dollars on the next news release.
Please take the time to review the New Company, ARTH below and add more shares of the SDIG and NSAV.
I see a huge week ahead and I want to thank Alethea for keeping up with the posting.
Look for more info as I see it on the News Wire.
Dave
The new company :
ARTH
Arch Therapeutics, Inc.
OTCQB Logo
Contact Info
20 William Street
Suite 270
Wellesley, MA 02481
Website: http://www.archtherapeutics.com
Phone: (617) 431-2313
Email: investors@archtherapeutics.com
OTCBB info for ARTH
company website
Above are the links to the company information and the OTCBB filings info. I have included all the information you will need to start your due diligence on ARTH. I will be expanding the portfolio all year by adding new companies. Archs CEO is now on a road show to talk about the companies new technology and raise capital at the same time.
The company appears to be well funded and has only sold 12 million shares to the market last year. They also have a low float of 72 million on the last 10q report.
We are waiting for the 10k report and the company looks to be very close to approval of the new invention.
They just finished uplisting to the OTCBB and they are collaborating with another large medical endorsement testing group.
Here is the headline :
Arch Therapeutics Negotiating a Collaboration Agreement With CURAM Centre for Research in Medical Devices
Collaboration Agreement Would Provide Additional Technical and Financial Support for Company's Research and Development Program, Including Clinical and Regulatory Activities Targeting Planned CE Mark
Looking for a reversal on the chart and we are at the possible bottom. When this approval comes in on the new invention this will go way up.
I look for more activity in the next couple of months into FDA approvals after the first of the year.
This appear to be a great time to add your bid and add this to the wave long term portfolio.
News & Analysis
Publish Date Headline Source
Oct 23, 2014 Arch Therapeutics Negotiating a Collaboration Agreement With CURAM Centre for Research in Medical Devices Marketwired
Sep 30, 2014 Arch Therapeutics Will Present at the Livingston Securities Life Sciences Stakeholders Summit on October 1, 2014 Marketwired
Sep 23, 2014 Arch Therapeutics Co-Founder Rutledge Ellis-Behnke to Speak at 12th International Conference on Neuroprotective Agents on September 29 Marketwired
Sep 16, 2014 Arch Therapeutics Co-Founder Rutledge Ellis-Behnke to Speak at 12th Annual Current Issues in Medicine, Biotech and Pharma Conference on September 18
Company Profile
Arch Therapeutics, Inc. is a medical device company developing a novel approach to stop bleeding (hemostasis) and control leaking (sealant) during surgery and trauma care. Arch is developing products based on an innovative self-assembling peptide technology platform to make surgery and interventional care faster and safer for patients. Arch's flagship development stage product candidate, known as AC5 Surgical Hemostatic Device™, is being designed to achieve hemostasis in minimally invasive and open surgical procedures.
Investor presentation
View our latest Corporate Presentation
Arch Therapeutics, Inc. Investor Presentation
Stock Information 10/31/2014 02:39 PM EDT
ARTH Symbol
OTCQB Market
$12.7M Market Cap
$0.1765 Price
$0.0115 Change
214,180 Volume
Go to Detailed Stock
ARTH Arch Therapeutics, Inc.: Summary, Stock Quote & Trades for Arch Therapeutics, Inc. - OTCM...
Get The Most Current Price Information On Arch Therapeutics, Inc. ARTH Including Quote Summary, Trade Data, Price History, 52 Week High, Low
View on www.otcmarkets.com
Preview by Yahoo
Arch Therapeutics, Inc.
Concept
Disruptive technology controls bleeding & leakage during surgery & trauma
“AC5 Surgical Hemostatic Device™ stops bleeding promptly. Unlike many competitive products, it conforms to irregular wound geometry, allows for normal healing, and helps maintain a clear field of vision.”
Physicians, industry and patients need a universal sealant for the challenges presented when an opening is created in the body, whether via surgery, trauma, colonoscopy biopsy, device implantation, or in consumer settings. The surgeon must manage and preferably prevent bleeding and leakage, as well as other challenges. Currently available tools to resolving these problems are often inadequate.
Arch intends to transform the landscape of interventional healthcare with products to seal and protect leaking and bleeding tissue. Arch’s solution elegantly controls the movement of bodily substances.
Arch’s products are not yet in human clinical trials, but are progressing in preclinical development. The first product, the AC5 Surgical Hemostatic Device,™ is designed to achieve hemostasis in minimally invasive (laparoscopic) and open surgical procedures.
Surgeons would deem the product a “must have” because of its tremendous features, making it very different and far advanced compared to anything else on the market today. AC5™ stops bleeding promptly. Unlike many competitive products, it conforms to irregular wound geometry, allows for normal healing, and helps maintain a clear field of vision. Because it is not sticky or glue-like, it is ideal for use in the laparoscopic setting – a challenge for much of the competition. Furthermore, it is transparent, enabling a surgeon to operate through it in order to prophylactically stop bleeding as it starts – we call this Crystal Clear Surgery™. Importantly, time to hemostasis (TTH) for AC5™ is typically measured in seconds, rather than the many minutes as required by much of the competition.
In preclinical tests, AC5™ has been simple, effective, and versatile. To date, biocompatibility has been excellent and healing of tissue treated with the device has been normal.
Co-founding and inventing scientist, Rutledge Ellis-Behnke, performs research on nanomedicine, tissue regeneration, neurocognitive topics, and a range of related areas. Examples of peer-reviewed articles are listed below.
Ellis-Behnke RG, Liang YX, Tay DKC, Kau PWF, Schneider GE, Zhang S, Wu W and So KF. (2006) Nano hemostat solution: immediate hemostasis at the nanoscale. Nanomedicine 2: 207-15.
Comments in Science, JAMA, Nature Biotechnology, Nature nanomedicine, etc.
Ellis-Behnke RG. (2011) At the nanoscale: nanohemostat, a new class of hemostatic agent. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 3: 70-8.
Sang LYH, Liang YX, Li Y, Wong, WM, Tay DKC, So KF, Ellis-Behnke RG, Wu WT, Cheung RTF. (2014) A self-assembling nanomaterial reduces acute brain injury and enhances functional recovery in a rat model of intracerebral hemorrhage.
Product
Hemostatic Agent: AC5™ for control over surgical bleeding.
The AC5 Surgical Hemostatic Device™ - more than just a better mousetrap
The hemostasis market is clearly in search of products that work better, faster, and more reliably. The AC5 Surgical Hemostatic Device™ is designed to do that. Arch believes its products will be significantly superior to what is currently available.
AC5™ is a synthetic peptide comprising naturally occurring amino acids. Evidence to-date supports that it is biocompatible. When squirted or sprayed onto a wound, AC5™ promptly intercalates into the nooks and crannies of the connective tissue where it builds itself into a physical, mechanical structure. That structure provides a barrier to leaking substances, including blood and other bodily fluids, regardless of type of surgery or, based on early data, clotting ability. Healing occurs normally.
The structural building process is called self-assembly, and it provides a new and improved approach to addressing “stasis and barrier applications.”
The Need: Modern Surgical Procedures
Drive Demand For Improved Therapies
ac5-PANEL-1.jpg
image
View on content.stockpr.com
Preview by Yahoo
ac5-PANEL-2.jpg
ac5-PANEL-3.jpg
Every day, around the world, millions of surgical procedures are taking place. Many are planned months in advance, while many more are in response to emergency needs.
Because these procedures are invasive, surgeons and other medical specialists focus on optimizing patient outcomes – and they constantly strive for fewer complications, including reduced fluid and blood loss in order to obtain the best results while maximizing safety and minimizing time to recovery. They also operate today through smaller incisions in the body, in procedures known as minimally invasive or laparoscopic surgery.
The Solution: AC5™ Stasis And Barrier Technology
ac5-PANEL-4.jpg
AC5™ itself is designed at the nano-scale. It's a synthetic peptide comprised of naturally occurring, non-animal, amino acids using straight-forward manufacturing techniques.
ac5-PANEL-5.jpg
AC5™ is applied directly onto a surgical or traumatic wound, where it rapidly creates a physical barrier in the nooks and crannies of the tissue and promptly stops bleeding and fluid leaks.
ac5-PANEL-6.jpg
It's not sticky or glue-like, and is very easy to prepare and handle. It's also a clear transparent gel enabling doctors to see through it as they work, performing “Crystal Clear Surgery™.”
The Result: Faster and Safer Surgical Outcomes
ac5-PANEL-7.jpg
Once applied, AC5™ works quickly to stop bleeding with rapid onset of hemostasis.
ac5-PANEL-8.jpg
With AC5™, surgeons are able to perform surgery through the protective barrier safely.
ac5-PANEL-9.jpg
Once the incision heals, AC5™ is naturally absorbed and passes from the body.
Nanomedicine.
, Liang YX, Tay DKC, Kau PWF, Schneider GE, Zhang S, Wu W and So KF. (2006) Nano hemostat solution: immediate hemostasis at the nanoscale. Nanomedicine 2: 207-15.
Comments in Science, JAMA, Nature Biotechnology, Nature nanomedicine, etc.
Ellis-Behnke RG. (2011) At the nanoscale: nanohemostat, a new class of hemostatic agent. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 3: 70-8.
Sang LYH, Liang YX, Li Y, Wong, WM, Tay DKC, So KF, Ellis-Behnke RG, Wu WT, Cheung RTF. (2014) A self-assembling nanomaterial reduces acute brain injury and enhances functional recovery in a rat model of intracerebral hemorrhage. Nanomedicine.
ARTH Security Details
Share Structure
Market Value1 $12,717,087 a/o Oct 31, 2014
Shares Outstanding 72,051,487 a/o Sep 30, 2014
Float Not Available
Authorized Shares 300,000,000 a/o Oct 15, 2014
Par Value 0.001
Shareholders
Shareholders of Record 66 a/o Dec 27, 2013
Corporate Actions
Ex. Date Record Date Pay Date
Dividend (0.00) May 28, 2013 May 24, 2013 May 24, 2013
Security Notes
Capital Change=shs increased by 11 for 1 split. Ex-date=05/28/2013. Rec date=05/24/2013. Pay date=05/24/2013.
Short Selling Data
Short Interest ARTH Arch Therapeutics, Inc.: Short Sale Data, Days to Cover for Arch Therapeutics, Inc. - OTCMarkets.com
Significant Failures to Deliver No
ARTH Arch Therapeutics, Inc.: Short Sale Data, Days to Cover for Arch Therapeutics, Inc. - OTCMa...
Analyze Shnort Sale Information On Arch Therapeutics, Inc. ARTH Including Short Interest, Days To Cover and Reg SHO Status
View on www.otcmarkets.com
Preview by Yahoo
Hello Waveriders,
Today we are introducing the next generation of digital music fun. StationDigital is starting this year well funded to become the first internet store that has rewards points just for listening and sharing the company.
The company is enticing the customers to take free products by frequenting the site and sharing this on your favorite social media to friends and family.
I have taken a long look at the brand new company as they reversed merged this summer. They have secured the funding and are just starting the process of huge growth onto the Internet streaming radio favorites. This is truly a very small float, with a reported 6 million shares on the market in the O/S. The total shares issued is 82 million at this time. They have established lines of credit and are starting the marketing process.
We truly are the first Wave of investors to look at this brand new company.
I look for a huge growth and a company we can actually take ownership pride in sharing are long term growth.
Below I have included links and what I see as the information we need to research for long term buys.
Please send me your thoughts on the company and what you like best.
https://sd-a.akamaihd.net/resource/imgs/logo2.png…
http://www.stationdigital.com/
10q description below:
StationDigital is the first truly next generation digital media broadcast platform. StationDigital's primary identity, as of 2014, is as a sophisticated pure play music discovery Internet radio service, offering a competitive, state of the art product to capture market share in the Internet radio space, and one with a unique, industry first value proposition: the StationDigital Listener Rewards Program, where all of our registered users earn listener rewards points every time they listen to StationDigital, either on the web or through any of our mobile apps, and for every time they share StationDigital with friends through social media, thus directly incentivizing our users for playing an active and ongoing part in the organic growth of our customer base and our brand. StationDigital rewards points can then be redeemed right inside our apps through the StationDigital online superstore for a wide variety of both physical and digital merchandise which is designed to appeal to users of all kinds.
StationDigital is also guided by a much more ambitious vision: to be the first free Internet radio platform to evolve into a comprehensive digital media broadcast platform, available on any device, anywhere, anytime. To that end, StationDigital intends to steadily add music videos, movies, television programming, specialty programming and video games to our platform of digital media and entertainment which will be available to our users at all times. We intend for our user rewards program to extend to each additional digital media offering on the StationDigital platform.
StationDigital Corporation (OTCQB: SDIG)
Highland Park Two
5700 Oakland Ave, #200
St. Louis, MO 63110
Share Price $0.40
Volume 8.05k
Shares Outstanding 82,341,826
Market Cap $32.94m
52 Week High $1.13
52 Week Low $0.19
as of 10/24/2014
Overview
.StationDigital is a free music streaming, live station and
recommendation service. Our playlists are made by music experts,
the service recommends various playlists based on search and user
activity. StationDigital offers playlists for the top artists and over 20mm
songs. Users can vote songs up or down, and the service will adapt
to the user's personal music preferences. Users can find playlists and
stations not just based on artists, songs, or genres, but also based on
themes, interests, location and eras. StationDigital is headquartered
in St. Louis, Missouri.
Management Team
Lou Rossi
Chief Executive Officer and Chairman
Terrance Taylor
CFO and Controller
Edward Storm
Chief Operating Officer
Lucky Romero
Vice President, Business Development
SDIG
StationDigital Corporation
OTCQB Logo
http://www.otcmarkets.com/stock/SDIG/profile
News & Analysis
Publish Date Headline Source
Sep 30, 2014 StationDigital Corporation Becomes a Member of the Collaborative Open Innovation ng Connect Program PR NEWSWIRE
Sep 29, 2014 StationDigital's Chairman and CEO Featured on Fox Business and Bloomberg PR NEWSWIRE
Sep 22, 2014 Consumers Enjoy Personalized Music and Video Content through Digital Media Discovery and Recommendation Platform StationDigital PR NEWSWIRE
Sep 11, 2014 StationDigital Corporation Secures DTC Eligibility - Investors Can Trade SDIG at Accelerated Pace PR NEWSWIRE
Sep 10, 2014 StationDigital Corporation is Going "Old School" at Florida State University - Title Sponsor of Three-Day Old School Charity and Football Support Event PR NEWSWIRE
Sep 2, 2014 StationDigital Corporation Appoints Industry Veteran Steve Marr to CFO PR NEWSWIRE
Aug 21, 2014 StationDigital Corporation Announces 17.6471 to 1 Forward Stock Split PR NEWSWIRE
Aug 11, 2014 StationDigital Corporation Approved for Name Change and New Ticker by FINRA PR NEWSWIRE
SEC Filings
Form Type Received Period Ending Size Report
8-K Sept 4, 2014 Sept 2, 2014 24.7 KB [PDF] PDF [RTF] RTF [HTML] HTML [Excel] XLS
8-K Aug 27, 2014 Aug 22, 2014 14.1 KB [PDF] PDF [RTF] RTF [HTML] HTML [Excel] XLS
10-Q/A Aug 20, 2014 Jun 30, 2014 1.1 MB [PDF] PDF [RTF] RTF [HTML] HTML [Excel] XLS
D Aug 20, 2014 8.5 KB [PDF] PDF [RTF] RTF [HTML] HTML
10-Q Aug 14, 2014 Jun 30, 2014 397.1 KB [PDF] PDF [RTF] RTF [HTML] HTML [Excel] XLS
SDIG Security Details
Share Structure
Market Value1 $32,936,730 a/o Oct 24, 2014
Shares Outstanding 82,341,826 a/o Sep 12, 2014
Float 6,000,000 a/o Jun 02, 2014
Authorized Shares 500,000,000 a/o Jun 02, 2014
Par Value 0.001
Shareholders
Shareholders of Record 52 a/o Jun 02, 2014
Corporate Actions
Ex. Date Record Date Pay Date
Dividend (0.00) Aug 25, 2014 Aug 21, 2014 Aug 22, 2014
Security Notes
Capital Change=shs increased by 17.6471 for 1 split. Ex-date=08/25/2014. Rec date=08/21/2014. Pay date=08/22/2014.
Short Selling Data
Short Interest 0 (-100%)
Oct 15, 2014
Significant Failures to Deliver No
Transfer Agent(s)
West Coast Stock Transfer Inc. - Transfer Agent - OTCMarkets.com
David Pecoraro
814-418-6648
davidpecoraro@rocketmail.com
OTC Markets | Official site of the OTCQX, OTCQB and OTC Pink Marketplaces featuring Free Stock &...
Get Current OTC Quote, Trade and Company Information for OTCQX, OTCQB, OTCBB,OTC Pink, Grey Market and penny stock Securities.
View on www.otcmarkets.com
Preview by Yahoo
http://www.stationdigital.com/
image
Listen to Free Streaming Music Only on Station Digital
Listen to free Streaming Music Video Radio Online on stationdigital.com. Music Player Search, Play & Share Latest Streaming Music Playlists for Free on Online Strea...
View on www.stationdigital...
Preview by Yahoo
David Pecoraro
Customer & Shareholder Relations Manager
Global distribution Inc.
Nutra Horizons
& Net savings Link,
OTC: NSAV
814-418-6648
davidpecoraro@rocketmail.com
david@nutrahorizon.net
david@globaldistributionincorp.net
http://www.netsavingslink.com/
https://www.facebook.com/…/Net-Savings-Link...6550714739
NutraHorizon - Coming Soon
http://www.nutrahorizon.net/
https://www.facebook.com/www.nutrahorizon.net
Today we are adding a new company to are growing list of companies.
Of course we still are featuring the NSAV and SDIG and today we are adding the ARTH.
I feel this is a great combination of price and different avenues of revenue streams.
The NSAV is internet and retail products and food. SDIG is in the internet streaming music and now we have a medical stock.
NSAV just started news this week and I see much more ahead for the company. our new president, Leonardo Genovese & Steven Baritz have been very active in meeting. They are adding a new distribution company that has existing products and revenues.
I look for this new Acquisition to close very quickly and much more for updates from both Steven and Leonardo.
Please add more as we are workign with Asher to allow us some breathing room on the price.
SDIG had a great slow start and seen record volume with an increase of 50% in the first week.
The company is starting up a new streaming music stations on the internet and will be giving away products for listening.
I see they are well funded and have not been diluting.
The company has a low public float recorded as 6 million shares.
By the move this week, I believe the market to be real tight n=on the shares and see a price breakout into dollars on the next news release.
Please take the time to review the New Company, ARTH below and add more shares of the SDIG and NSAV.
I see a huge week ahead and I want to thank Alethea for keeping up with the posting.
Look for more info as I see it on the News Wire.
Dave
The new company :
ARTH
Arch Therapeutics, Inc.
OTCQB Logo
Contact Info
20 William Street
Suite 270
Wellesley, MA 02481
Website: http://www.archtherapeutics.com
Phone: (617) 431-2313
Email: investors@archtherapeutics.com
OTCBB info for ARTH
company website
Above are the links to the company information and the OTCBB filings info. I have included all the information you will need to start your due diligence on ARTH. I will be expanding the portfolio all year by adding new companies. Archs CEO is now on a road show to talk about the companies new technology and raise capital at the same time.
The company appears to be well funded and has only sold 12 million shares to the market last year. They also have a low float of 72 million on the last 10q report.
We are waiting for the 10k report and the company looks to be very close to approval of the new invention.
They just finished uplisting to the OTCBB and they are collaborating with another large medical endorsement testing group.
Here is the headline :
Arch Therapeutics Negotiating a Collaboration Agreement With CURAM Centre for Research in Medical Devices
Collaboration Agreement Would Provide Additional Technical and Financial Support for Company's Research and Development Program, Including Clinical and Regulatory Activities Targeting Planned CE Mark
Looking for a reversal on the chart and we are at the possible bottom. When this approval comes in on the new invention this will go way up.
I look for more activity in the next couple of months into FDA approvals after the first of the year.
This appear to be a great time to add your bid and add this to the wave long term portfolio.
News & Analysis
Publish Date Headline Source
Oct 23, 2014 Arch Therapeutics Negotiating a Collaboration Agreement With CURAM Centre for Research in Medical Devices Marketwired
Sep 30, 2014 Arch Therapeutics Will Present at the Livingston Securities Life Sciences Stakeholders Summit on October 1, 2014 Marketwired
Sep 23, 2014 Arch Therapeutics Co-Founder Rutledge Ellis-Behnke to Speak at 12th International Conference on Neuroprotective Agents on September 29 Marketwired
Sep 16, 2014 Arch Therapeutics Co-Founder Rutledge Ellis-Behnke to Speak at 12th Annual Current Issues in Medicine, Biotech and Pharma Conference on September 18
Company Profile
Arch Therapeutics, Inc. is a medical device company developing a novel approach to stop bleeding (hemostasis) and control leaking (sealant) during surgery and trauma care. Arch is developing products based on an innovative self-assembling peptide technology platform to make surgery and interventional care faster and safer for patients. Arch's flagship development stage product candidate, known as AC5 Surgical Hemostatic Device™, is being designed to achieve hemostasis in minimally invasive and open surgical procedures.
Investor presentation
View our latest Corporate Presentation
Arch Therapeutics, Inc. Investor Presentation
Stock Information 10/31/2014 02:39 PM EDT
ARTH Symbol
OTCQB Market
$12.7M Market Cap
$0.1765 Price
$0.0115 Change
214,180 Volume
Go to Detailed Stock
ARTH Arch Therapeutics, Inc.: Summary, Stock Quote & Trades for Arch Therapeutics, Inc. - OTCM...
Get The Most Current Price Information On Arch Therapeutics, Inc. ARTH Including Quote Summary, Trade Data, Price History, 52 Week High, Low
View on www.otcmarkets.com
Preview by Yahoo
Arch Therapeutics, Inc.
Concept
Disruptive technology controls bleeding & leakage during surgery & trauma
“AC5 Surgical Hemostatic Device™ stops bleeding promptly. Unlike many competitive products, it conforms to irregular wound geometry, allows for normal healing, and helps maintain a clear field of vision.”
Physicians, industry and patients need a universal sealant for the challenges presented when an opening is created in the body, whether via surgery, trauma, colonoscopy biopsy, device implantation, or in consumer settings. The surgeon must manage and preferably prevent bleeding and leakage, as well as other challenges. Currently available tools to resolving these problems are often inadequate.
Arch intends to transform the landscape of interventional healthcare with products to seal and protect leaking and bleeding tissue. Arch’s solution elegantly controls the movement of bodily substances.
Arch’s products are not yet in human clinical trials, but are progressing in preclinical development. The first product, the AC5 Surgical Hemostatic Device,™ is designed to achieve hemostasis in minimally invasive (laparoscopic) and open surgical procedures.
Surgeons would deem the product a “must have” because of its tremendous features, making it very different and far advanced compared to anything else on the market today. AC5™ stops bleeding promptly. Unlike many competitive products, it conforms to irregular wound geometry, allows for normal healing, and helps maintain a clear field of vision. Because it is not sticky or glue-like, it is ideal for use in the laparoscopic setting – a challenge for much of the competition. Furthermore, it is transparent, enabling a surgeon to operate through it in order to prophylactically stop bleeding as it starts – we call this Crystal Clear Surgery™. Importantly, time to hemostasis (TTH) for AC5™ is typically measured in seconds, rather than the many minutes as required by much of the competition.
In preclinical tests, AC5™ has been simple, effective, and versatile. To date, biocompatibility has been excellent and healing of tissue treated with the device has been normal.
Co-founding and inventing scientist, Rutledge Ellis-Behnke, performs research on nanomedicine, tissue regeneration, neurocognitive topics, and a range of related areas. Examples of peer-reviewed articles are listed below.
Ellis-Behnke RG, Liang YX, Tay DKC, Kau PWF, Schneider GE, Zhang S, Wu W and So KF. (2006) Nano hemostat solution: immediate hemostasis at the nanoscale. Nanomedicine 2: 207-15.
Comments in Science, JAMA, Nature Biotechnology, Nature nanomedicine, etc.
Ellis-Behnke RG. (2011) At the nanoscale: nanohemostat, a new class of hemostatic agent. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 3: 70-8.
Sang LYH, Liang YX, Li Y, Wong, WM, Tay DKC, So KF, Ellis-Behnke RG, Wu WT, Cheung RTF. (2014) A self-assembling nanomaterial reduces acute brain injury and enhances functional recovery in a rat model of intracerebral hemorrhage.
Product
Hemostatic Agent: AC5™ for control over surgical bleeding.
The AC5 Surgical Hemostatic Device™ - more than just a better mousetrap
The hemostasis market is clearly in search of products that work better, faster, and more reliably. The AC5 Surgical Hemostatic Device™ is designed to do that. Arch believes its products will be significantly superior to what is currently available.
AC5™ is a synthetic peptide comprising naturally occurring amino acids. Evidence to-date supports that it is biocompatible. When squirted or sprayed onto a wound, AC5™ promptly intercalates into the nooks and crannies of the connective tissue where it builds itself into a physical, mechanical structure. That structure provides a barrier to leaking substances, including blood and other bodily fluids, regardless of type of surgery or, based on early data, clotting ability. Healing occurs normally.
The structural building process is called self-assembly, and it provides a new and improved approach to addressing “stasis and barrier applications.”
The Need: Modern Surgical Procedures
Drive Demand For Improved Therapies
ac5-PANEL-1.jpg
image
View on content.stockpr.com
Preview by Yahoo
ac5-PANEL-2.jpg
ac5-PANEL-3.jpg
Every day, around the world, millions of surgical procedures are taking place. Many are planned months in advance, while many more are in response to emergency needs.
Because these procedures are invasive, surgeons and other medical specialists focus on optimizing patient outcomes – and they constantly strive for fewer complications, including reduced fluid and blood loss in order to obtain the best results while maximizing safety and minimizing time to recovery. They also operate today through smaller incisions in the body, in procedures known as minimally invasive or laparoscopic surgery.
The Solution: AC5™ Stasis And Barrier Technology
ac5-PANEL-4.jpg
AC5™ itself is designed at the nano-scale. It's a synthetic peptide comprised of naturally occurring, non-animal, amino acids using straight-forward manufacturing techniques.
ac5-PANEL-5.jpg
AC5™ is applied directly onto a surgical or traumatic wound, where it rapidly creates a physical barrier in the nooks and crannies of the tissue and promptly stops bleeding and fluid leaks.
ac5-PANEL-6.jpg
It's not sticky or glue-like, and is very easy to prepare and handle. It's also a clear transparent gel enabling doctors to see through it as they work, performing “Crystal Clear Surgery™.”
The Result: Faster and Safer Surgical Outcomes
ac5-PANEL-7.jpg
Once applied, AC5™ works quickly to stop bleeding with rapid onset of hemostasis.
ac5-PANEL-8.jpg
With AC5™, surgeons are able to perform surgery through the protective barrier safely.
ac5-PANEL-9.jpg
Once the incision heals, AC5™ is naturally absorbed and passes from the body.
Nanomedicine.
, Liang YX, Tay DKC, Kau PWF, Schneider GE, Zhang S, Wu W and So KF. (2006) Nano hemostat solution: immediate hemostasis at the nanoscale. Nanomedicine 2: 207-15.
Comments in Science, JAMA, Nature Biotechnology, Nature nanomedicine, etc.
Ellis-Behnke RG. (2011) At the nanoscale: nanohemostat, a new class of hemostatic agent. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 3: 70-8.
Sang LYH, Liang YX, Li Y, Wong, WM, Tay DKC, So KF, Ellis-Behnke RG, Wu WT, Cheung RTF. (2014) A self-assembling nanomaterial reduces acute brain injury and enhances functional recovery in a rat model of intracerebral hemorrhage. Nanomedicine.
ARTH Security Details
Share Structure
Market Value1 $12,717,087 a/o Oct 31, 2014
Shares Outstanding 72,051,487 a/o Sep 30, 2014
Float Not Available
Authorized Shares 300,000,000 a/o Oct 15, 2014
Par Value 0.001
Shareholders
Shareholders of Record 66 a/o Dec 27, 2013
Corporate Actions
Ex. Date Record Date Pay Date
Dividend (0.00) May 28, 2013 May 24, 2013 May 24, 2013
Security Notes
Capital Change=shs increased by 11 for 1 split. Ex-date=05/28/2013. Rec date=05/24/2013. Pay date=05/24/2013.
Short Selling Data
Short Interest ARTH Arch Therapeutics, Inc.: Short Sale Data, Days to Cover for Arch Therapeutics, Inc. - OTCMarkets.com
Significant Failures to Deliver No
ARTH Arch Therapeutics, Inc.: Short Sale Data, Days to Cover for Arch Therapeutics, Inc. - OTCMa...
Analyze Shnort Sale Information On Arch Therapeutics, Inc. ARTH Including Short Interest, Days To Cover and Reg SHO Status
View on www.otcmarkets.com
Preview by Yahoo
Hello Waveriders,
Today we are introducing the next generation of digital music fun. StationDigital is starting this year well funded to become the first internet store that has rewards points just for listening and sharing the company.
The company is enticing the customers to take free products by frequenting the site and sharing this on your favorite social media to friends and family.
I have taken a long look at the brand new company as they reversed merged this summer. They have secured the funding and are just starting the process of huge growth onto the Internet streaming radio favorites. This is truly a very small float, with a reported 6 million shares on the market in the O/S. The total shares issued is 82 million at this time. They have established lines of credit and are starting the marketing process.
We truly are the first Wave of investors to look at this brand new company.
I look for a huge growth and a company we can actually take ownership pride in sharing are long term growth.
Below I have included links and what I see as the information we need to research for long term buys.
Please send me your thoughts on the company and what you like best.
https://sd-a.akamaihd.net/resource/imgs/logo2.png…
http://www.stationdigital.com/
10q description below:
StationDigital is the first truly next generation digital media broadcast platform. StationDigital's primary identity, as of 2014, is as a sophisticated pure play music discovery Internet radio service, offering a competitive, state of the art product to capture market share in the Internet radio space, and one with a unique, industry first value proposition: the StationDigital Listener Rewards Program, where all of our registered users earn listener rewards points every time they listen to StationDigital, either on the web or through any of our mobile apps, and for every time they share StationDigital with friends through social media, thus directly incentivizing our users for playing an active and ongoing part in the organic growth of our customer base and our brand. StationDigital rewards points can then be redeemed right inside our apps through the StationDigital online superstore for a wide variety of both physical and digital merchandise which is designed to appeal to users of all kinds.
StationDigital is also guided by a much more ambitious vision: to be the first free Internet radio platform to evolve into a comprehensive digital media broadcast platform, available on any device, anywhere, anytime. To that end, StationDigital intends to steadily add music videos, movies, television programming, specialty programming and video games to our platform of digital media and entertainment which will be available to our users at all times. We intend for our user rewards program to extend to each additional digital media offering on the StationDigital platform.
StationDigital Corporation (OTCQB: SDIG)
Highland Park Two
5700 Oakland Ave, #200
St. Louis, MO 63110
Share Price $0.40
Volume 8.05k
Shares Outstanding 82,341,826
Market Cap $32.94m
52 Week High $1.13
52 Week Low $0.19
as of 10/24/2014
Overview
.StationDigital is a free music streaming, live station and
recommendation service. Our playlists are made by music experts,
the service recommends various playlists based on search and user
activity. StationDigital offers playlists for the top artists and over 20mm
songs. Users can vote songs up or down, and the service will adapt
to the user's personal music preferences. Users can find playlists and
stations not just based on artists, songs, or genres, but also based on
themes, interests, location and eras. StationDigital is headquartered
in St. Louis, Missouri.
Management Team
Lou Rossi
Chief Executive Officer and Chairman
Terrance Taylor
CFO and Controller
Edward Storm
Chief Operating Officer
Lucky Romero
Vice President, Business Development
SDIG
StationDigital Corporation
OTCQB Logo
http://www.otcmarkets.com/stock/SDIG/profile
News & Analysis
Publish Date Headline Source
Sep 30, 2014 StationDigital Corporation Becomes a Member of the Collaborative Open Innovation ng Connect Program PR NEWSWIRE
Sep 29, 2014 StationDigital's Chairman and CEO Featured on Fox Business and Bloomberg PR NEWSWIRE
Sep 22, 2014 Consumers Enjoy Personalized Music and Video Content through Digital Media Discovery and Recommendation Platform StationDigital PR NEWSWIRE
Sep 11, 2014 StationDigital Corporation Secures DTC Eligibility - Investors Can Trade SDIG at Accelerated Pace PR NEWSWIRE
Sep 10, 2014 StationDigital Corporation is Going "Old School" at Florida State University - Title Sponsor of Three-Day Old School Charity and Football Support Event PR NEWSWIRE
Sep 2, 2014 StationDigital Corporation Appoints Industry Veteran Steve Marr to CFO PR NEWSWIRE
Aug 21, 2014 StationDigital Corporation Announces 17.6471 to 1 Forward Stock Split PR NEWSWIRE
Aug 11, 2014 StationDigital Corporation Approved for Name Change and New Ticker by FINRA PR NEWSWIRE
SEC Filings
Form Type Received Period Ending Size Report
8-K Sept 4, 2014 Sept 2, 2014 24.7 KB [PDF] PDF [RTF] RTF [HTML] HTML [Excel] XLS
8-K Aug 27, 2014 Aug 22, 2014 14.1 KB [PDF] PDF [RTF] RTF [HTML] HTML [Excel] XLS
10-Q/A Aug 20, 2014 Jun 30, 2014 1.1 MB [PDF] PDF [RTF] RTF [HTML] HTML [Excel] XLS
D Aug 20, 2014 8.5 KB [PDF] PDF [RTF] RTF [HTML] HTML
10-Q Aug 14, 2014 Jun 30, 2014 397.1 KB [PDF] PDF [RTF] RTF [HTML] HTML [Excel] XLS
SDIG Security Details
Share Structure
Market Value1 $32,936,730 a/o Oct 24, 2014
Shares Outstanding 82,341,826 a/o Sep 12, 2014
Float 6,000,000 a/o Jun 02, 2014
Authorized Shares 500,000,000 a/o Jun 02, 2014
Par Value 0.001
Shareholders
Shareholders of Record 52 a/o Jun 02, 2014
Corporate Actions
Ex. Date Record Date Pay Date
Dividend (0.00) Aug 25, 2014 Aug 21, 2014 Aug 22, 2014
Security Notes
Capital Change=shs increased by 17.6471 for 1 split. Ex-date=08/25/2014. Rec date=08/21/2014. Pay date=08/22/2014.
Short Selling Data
Short Interest 0 (-100%)
Oct 15, 2014
Significant Failures to Deliver No
Transfer Agent(s)
West Coast Stock Transfer Inc. - Transfer Agent - OTCMarkets.com
David Pecoraro
814-418-6648
davidpecoraro@rocketmail.com
OTC Markets | Official site of the OTCQX, OTCQB and OTC Pink Marketplaces featuring Free Stock &...
Get Current OTC Quote, Trade and Company Information for OTCQX, OTCQB, OTCBB,OTC Pink, Grey Market and penny stock Securities.
View on www.otcmarkets.com
Preview by Yahoo
http://www.stationdigital.com/
image
Listen to Free Streaming Music Only on Station Digital
Listen to free Streaming Music Video Radio Online on stationdigital.com. Music Player Search, Play & Share Latest Streaming Music Playlists for Free on Online Strea...
View on www.stationdigital...
Preview by Yahoo
David Pecoraro
Customer & Shareholder Relations Manager
Global distribution Inc.
Nutra Horizons
& Net savings Link,
OTC: NSAV
814-418-6648
davidpecoraro@rocketmail.com
david@nutrahorizon.net
david@globaldistributionincorp.net
http://www.netsavingslink.com/
https://www.facebook.com/…/Net-Savings-Link...6550714739
NutraHorizon - Coming Soon
http://www.nutrahorizon.net/
https://www.facebook.com/www.nutrahorizon.net
